Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients

摘要

OBJECTIVES: To study the effect of pioglitazone (PIO) on plasma resistin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) in patients with type II diabetes (T2DM).SUBJECTS: A total of 13 T2DM patients (age=512y, BMI=29.71.1kg/m2, HbA1c=8.00.5%).METHODS: HFC (magnetic resonance spectroscopy) and basal plasma resistin concentration were quantitated before and after PIO treatment (45mg/day) for 16 weeks. Subjects received a 3h euglycemic insulin (100mU/m2/min) clamp with 3-[3H] glucose to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO.RESULTS: PIO reduced fasting plasma glucose (10.30.7 to 7.60.6mmol/l, P1c (8.00.4 to 6.80.3%, PPPPPPr=0.58, Pr=0.55, Pr=0.66, Pr=0.41, Pr=-0.18, P=NS) or after (r=-0.13, P=NS) PIO treatment.CONCLUSIONS: PIO treatment in T2DM causes a significant decrease in plasma resistin concentration. The decrease in plasma resistin is positively correlated with the decrease in hepatic fat content and improvement in hepatic insulin sensitivity.